Loading stock data…
$2.50-0.02 (-0.60%)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Minerva Neurosciences, Inc. in the Healthcare sector is trading at $2.50 with a market capitalization of $197M. Wall Street consensus targets $10.33 (3 analysts), implying a +313.3% move over the next 12 months. The stock is currently near its 52-week low of $2.39, remaining 50.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.64M↑ | -$16.67M↓ | -$4.98M↓ | -$2.84M↑ | -$3.37M |
| Net Income | $17.47M↑ | -$125.40M↑ | -$283.67M↓ | -$2.74M↑ | -$3.26M |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is...